Competitive Technologies Signs Agreement for Dental Use of Nanotechnology Bone Biomaterial

Sep 20, 2004, 01:00 ET from Competitive Technologies, Inc.

    FAIRFIELD, Conn., Sept. 20 /PRNewswire-FirstCall/ -- Competitive
 Technologies, Inc. (Amex:   CTT) announced today that it has granted an
 exclusive option to research the manufacture and use of CTT's nanotechnology
 bone biomaterial for dental applications to a major, diverse dental products
 company. CTT has an exclusive agreement with the University of South Carolina
 Research Foundation (USCRF) to license and commercialize this nanotechnology.
 The technology, an injectible calcium phosphate-based biomaterial, is from the
 work of Dr. Brian Genge, a research professor in the Department of Chemistry
 and Biochemistry at the University of South Carolina.
     "The agreement to develop products using USCRF's innovative nanoparticle
 biomaterial technology in the dental products market is an example of CTT
 fulfilling unsatisfied market needs from its portfolio of technology
 solutions," said Suzanne N. B. Alent, CTT's VP Marketing and Business
 Development. "This agreement establishes CTT as a value-added partner in the
 dental medical device industry."
     Applications in this agreement are for dental use. The technology can also
 be applied to human bones, especially related to the spine, and veterinary
 uses. The bone biomaterial technology is an easily flowable, moldable paste
 that conforms to and interdigitates with the host bone. It rapidly hardens
 itself in vivo, forming a solid bone-like structure capable of stabilizing
 fractured bone within 15 minutes. The technology has superior compressive
 strength making it suitable for weight and non-weight bearing bones, and is
 both machinable and drillable.
     John B. Nano, CTT's President and CEO said, "Bone biomaterial is just one
 of the important innovative technologies in our exciting portfolio. CTT is
 actively marketing and commercializing several technologies, including
 homocysteine assays, sexual dysfunction treatment, video compression and
 decoding technology, sunless tanning application, silicon carbide wafer
 testing, animated graphical password security technology, language-mastering
 software, specialty chemical compounds, pollution abatement process, and the
 Therapik(R) thermal therapy."
     About Competitive Technologies, Inc.
     Competitive Technologies, established in 1968, is a full service
 technology transfer and licensing provider focused on the technology needs of
 its customers and transforming those requirements into commercially viable
 solutions. CTT is a global leader in identifying, developing and
 commercializing innovative technologies in life, digital, nano, and physical
 sciences developed by universities, companies and inventors. The global market
 for technology transfer services is estimated at $150 billion annually. CTT
 maximizes the value of intellectual assets for the benefit of its customers,
 clients and shareholders. Visit CTT's website:
     Statements about our future expectations, including development and
 regulatory plans, and all other statements in this document other than
 historical facts are "forward-looking statements" within the meaning of
 applicable Federal Securities Laws, and are not guarantees of future
 performance. These statements involve risks and uncertainties inherent in our
 business, including those set forth under the caption "Risk Factors" in our
 Prospectus filed with the SEC on May 6, 2004 under Rule 424 (b)(3) of the
 Securities Act of 1933, and other factors that may be described in our other
 filings with the SEC, and are subject to change at any time. Our actual
 results could differ materially from these forward-looking statements. We
 undertake no obligation to update publicly any forward-looking statement.
     Direct inquiries to:
      Johnnie D. Johnson, Strategic IR, Inc. E-mail:
      Tel. (212) 754-6565; Fax (212) 754-4333 E-mail:

SOURCE Competitive Technologies, Inc.